From 3D spheroids to tumor bearing mice: efficacy and distribution studies of trastuzumab-docetaxel immunoliposome in breast cancer [Erratum]

Rodallec A, Sicard G, Giacometti S, et al. Int J Nano. 2018;13: 6677–6688.  

On page 6684, Table 1 should be as follows:

Table 1

| Treatment                      | Beginning of treatment (×10^4) | End of treatment (×10^4) |
|--------------------------------|-------------------------------|--------------------------|
| **MDA-MB-453 bearing mice**   |                               |                          |
| Control                        | 1.15                          | 1.73                     |
| Liposome + free trastuzumab    | 0.877                         | 2.53                     |
| Immunoliposome                 | 1.70                          | 1.72                     |
| **MDA-MB-231 bearing mice**   |                               |                          |
| Control                        | 1.19                          | 5.96                     |
| Liposome + free trastuzumab    | 1.49                          | 3.88                     |
| Immunoliposome                 | 1.38                          | 3.44                     |